The objectives of this study were 1) to determine whether a zenith in bone formation (indicated by circulating osteocalcin) existed at night in early life, and 2) to compare the effects of three different dexamethasone (DEX) treatment regimens on bone turnover, bone mineral content, and growth. Three DEX treatment regimens were tested in 8-d-old piglets (n ϭ 8/group): 1) low evening dose of DEX (0.5 mg/kg/d) as 70% in the morning and 30% in the evening for 10 d; 2) tapering course of DEX (0.5, 0.3, and 0.2 mg/kg/d) as 50% in the morning and 50% in the evening for 14 d; and 3) constant dose of DEX (0.5 mg/kg/d) as 50% in the morning and 50% in the evening for 10 d. Oral water placebo groups were tested with the same time courses. At pretreatment, plasma osteocalcin was significantly higher (p Ͻ 0.05) at 0100 than at 0900 and 1700. At necropsy, measures for DEX groups were calculated as Z-scores using values from the placebo groups. The low evening DEX dose led to a significantly lower reduction in plasma osteocalcin compared with the tapered and constant dosing regimens (p Ͻ 0.05). The significant weight reduction in the DEX group occurred at d 9 in the low evening dose regimen but at d 7 in the constant dosing regimen, compared with the placebo group. Bone mineral content Z-score was reduced similarly in all DEX-treated groups across the three dosing regimens. We conclude that a plasma osteocalcin zenith at night exists in early life. A high DEX dose in the morning and low DEX dose in the evening may partially attenuate corticosteroid-induced suppression of bone formation and growth restriction. Abbreviations BMC, bone mineral content Cr, creatinine CV, coefficient of variation DEX, dexamethasone NTx, N-terminal telopeptide of type I collagen VLBW, very low birth weight VLBW infants may develop severely compromised lung function because of their immaturity. The incidence of bronchopulmonary dysplasia in VLBW infants has been reported to be as high as 70% (1). DEX is prescribed for these infants to improve pulmonary compliance and to facilitate earlier weaning from the ventilator (2, 3). However, linear, weight and bone growth can be adversely affected by DEX administration in VLBW infants (4 -7). Despite these side effects, DEX continues to be used in treatment of chronic lung disease (8 -10). Although both tapered (3-6) and constant (8) dosing regimens are used in clinical practice, it is not known whether they induce similar restrictions in growth and bone development.
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The rapidly growing piglet is a good model for human infants (11) . From our experience with piglets, monitoring growth for a 2-wk period (12, 13) parallels the changes in weight (4-fold increase) and length (1.2-fold increase) that we observe in VLBW human infants over 8.5 wk or from their birth to term-adjusted age (4). Piglets respond like human infants in the metabolic processing of minerals, and they have been used successfully to measure responses in growth and bone development to alterations in dietary minerals (14) , administration of DEX (12, 13) , and GH treatment (12) .
Corticosteroids adversely alter skeletal metabolism through multiple pathways, such as inhibition of intestinal calcium absorption (13) , increased osteoclast-mediated bone resorption (15) , direct stimulation of renal excretion of calcium (15) , and the direct suppression of bone formation (16) . A circadian rhythm in bone formation has been reported in adults and children, with a zenith at night and nadir in the morning (17, 18) . Circadian rhythm in bone formation has not been assessed in infants; possibly because of the difficulty of collecting serial blood samples from newborn infants. If a zenith at night in bone formation exists in early life, it would be clinically useful to administer a higher morning dose and a lower evening dose of DEX. Such a low evening dosing regimen may potentially attenuate DEX-induced suppression of bone formation at the night zenith.
This study was designed using the infant piglet model with the objectives 1) to observe whether a zenith in bone formation exists at night in early life; and 2) to compare the effects of three DEX treatment regimens-low evening/high morning dose, tapered dose, or constant dose-on bone turnover, BMC, and growth.
METHODS
Animals and care. Forty-eight 5-d-old male Yorkshire piglets were removed from the sow at the Swine Research Facility, Arkell Farms (Guelph, Ontario, Canada) and transported to the McMaster University Central Animal Facility. All procedures were in agreement with the Guide for the Care and Use of Experimental Animals (19) and were approved by the McMaster Animal Research Ethics Board. Piglets were housed in stainless steel metabolic cages under heat lamps that maintained an ambient temperature of 28 -30°C. The piglets were fed an artificial formula that provided energy (3344 kJ/L), protein (40 g/L), vitamins, and minerals in accordance with the nutrient requirements for growing piglets (13) . Warmed formula (400 mL/kg/d) was offered in equal amounts four times per day based on the piglets' fasting morning weight.
Study design. Piglets were adapted to formula and the environment for 3 d and then were block randomized to DEX (sodium phosphate salt Hexadrol; Orgaon Teknika, Toronto, Canada) or placebo vehicle within low evening dosing, tapered dosing, or constant dosing regimens (n ϭ 8 for each group) when they were 8 d old (Fig. 1 ). This DEX protocol mimics the dosing regimens used in the management of VLBW infants. DEX and placebo in doses noted in Figure 1 were administered by orogastric gavage technique. At necropsy day, the cumulative dose of DEX was 13.9, 14.0, and 13.9 mg, respectively, in low evening, tapered, and constant dosing regimens.
Sampling. Blood was collected at 0900 in a nonfed state on the day before DEX treatment (d 0) as the baseline sample, and at necropsy (d 11 for low evening dose and constant dose regimens and d 15 for tapered dose regimen). In the low evening dose study, baseline blood was also collected at 1700 and 0100 randomly in a subset of piglets (four from the DEX group and four from the placebo group) to assess the zenith of bone formation. Blood was collected in all piglets by a blind stab of the interior jugular at baseline and by a cardiac puncture at end of treatment while the piglets were under light anesthesia (isoflurane gas, Aerrane; Anaquest, Mississauga, Ontario, Canada). Time to recovery after anesthesia was 5 minutes. Urine was collected for 24 h at baseline and the day before necropsy. Twenty-four-hour urine was collected in dishes placed under the metabolic cages. All blood samples were stored at Ϫ70°C, and urine samples were stored at Ϫ20°C, until analyzed. Whole-body BMC was analyzed in the evening before the necropsy day. Body weight was measured daily on a digital scale. Body length was measured at baseline and at necropsy while piglets were anesthetized for blood sampling. Femoral length was measured at necropsy day in excised bone.
Methods of analyses. Plasma osteocalcin (Bone Gla-protein, BGP), used as a bone formation marker, was measured by RIA (DiaSorin Inc, Stillwater, MN, U.S.A.) with purified bovine osteocalcin as standard and tracer and rabbit antiserum to bovine osteocalcin. The intraassay CV calculated from duplicates was 6.7%. The interassay CV previously reported from our laboratory was 6.1% (14) . Twenty-four-hour urinary NTx, used as a bone resorption marker, was measured by ELISA (Osteomark, NTX Urine, Ostex International, Inc., Seattle, WA, U.S.A.). Triplicate analysis of two piglet samples at three different concentrations demonstrated the linearity of the assay with correlation coefficients of 0.99, similar to the correlation coefficients reported in human samples by Ostex International Inc. Assay values were standardized to an equivalent amount of bone collagen, and were expressed in nanomoles bone collagen equivalents (BCE) as a ratio to body weight. The intraassay CV calculated from duplicates was 6.6%, and the interassay CV previously reported from our laboratory was 5.7% (12) . Plasma BGP measured by RIA and urinary NTx measured by ELISA have been proved to be reliable and sensitive in pig samples (12, 13, 20, 21) . Plasma cortisol was . Piglets were placed on the scan field in a spread-eagle position. Placement CV for the whole-body BMC was 1.2% (22) . Statistical analysis. During treatment and at necropsy day, piglets treated with placebo for 10 d in the constant and low evening dosing regimens were combined as one control group (n ϭ 16), whereas piglets treated with placebo for 14 d were used as controls (n ϭ 8) for piglets treated with a tapered course of DEX for 14 d. Measures for DEX groups were calculated as Z-scores at the necropsy day. The Z-scores for constant and low evening dosing regimens were derived from those control piglets treated with placebo for 10 d (n ϭ 16), whereas the Z-scores for tapered dosing regimen were derived from its own corresponding control piglets, which were treated with placebo for 14 d (n ϭ 8). Repeated measures ANOVA with Bonferroni correction was used to assess the plasma osteocalcin at 0900, 1700, and 0100. All other statistical comparisons were performed using one-way ANOVA with Bonferroni correction.
RESULTS
At baseline, there were no differences in body weight, length, or biochemical markers of bone turnover among the three placebo groups. The baseline measurements also did not differ between DEX groups and controls, which represented the combined placebo groups in the three studies (n ϭ 24; Table  1 ). The energy intake for all piglets is reported in Table 2 . Plasma osteocalcin measured at 0100 was 45.1 Ϯ 7.5 ng/mL (mean Ϯ SD), which is significantly higher than that measured at 0900 (25.4 Ϯ 6.1 ng/mL) and at 1700 (27.8 Ϯ 7.4 ng/mL; Fig. 2 ).
Body weights in the three DEX-treated groups were all significantly lower than those in placebo groups at the necropsy day (Fig. 3) . A significant body weight difference between the DEX group and placebo group occurred at d 7 in the constant dosing regimen but at d 9 in the low evening dosing regimen (Fig. 3) .
At necropsy day, plasma cortisol in control piglets was 2701 Ϯ 894 ng/dL (mean Ϯ SD) which is significantly higher than cortisol in piglets treated with constant dosing (919 Ϯ 443 ng/dL) and low evening dosing (1107 Ϯ 528 ng/dL) regimens 
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(p Ͻ 0.05). Plasma cortisol did not differ between the two DEX treatment groups (Fig. 4) . BMC, body weight and length, femoral length, plasma osteocalcin, and urinary NTx/weight in the three DEX-treated groups were all significantly lower than those in corresponding placebo groups at necropsy day. When the three dosing regimens were compared, Z-scores for BMC, body weight and length, urinary NTx/weight, and femoral length did not differ among the three DEX groups (Fig. 5) . However, the low evening dosing regimen attenuated the reduction in plasma osteocalcin significantly compared with the tapered dosing and constant dosing regimens (Fig. 5) .
DISCUSSION
Osteocalcin, a sensitive bone formation marker, was reported previously in adults and children to have a zenith at night and nadir in the morning (17, 18) . In the present study, a similar nocturnal zenith in plasma osteocalcin was observed in infant piglets. The factors controlling this rhythm are unclear. In children and adults, a circadian rhythm in bone formation paralleled that observed for circulating cortisol (17, 23) and PTH (24) but was relatively unaffected by age, sex hormone status, sex (25) , or bed rest (26) . A longitudinal study measuring human infant salivary cortisol, reflecting the free fraction of plasma cortisol, demonstrated that a diurnal rhythm for cortisol occurs as early as 2 wk of age (27) . Therefore, plasma cortisol may also regulate the circadian rhythm in bone formation during infancy. 
THREE DEX TREATMENT REGIMENS IN PIGLETS
In the present study, we demonstrated that endogenous cortisol was inhibited during DEX treatment, which is consistent with a previous study in human infants (28) . Thus, the exogenous DEX treatment, rather than the endogenous cortisol, may be the major regulator for circulating osteocalcin. By using a low evening dosing regimen with high DEX dose (70%) in the morning and low DEX dose (30%) in the evening, we demonstrated that corticosteroid-induced suppression of bone formation as determined by plasma osteocalcin and growth as determined by body weight were partially attenuated. Thus, the low evening dose of DEX may allow for a more normal physiologic milieu of growth factors to be operational during the night.
The Z-scores for body weight did not differ among the three treatment regimens at the necropsy day as determined by one-way ANOVA. Interpretation of the body weight may be limited by the relatively small sample size and the multiple comparisons. Application of a Bonferroni adjustment for multiple comparisons suggests that only p Ͻ 0.0167 should be considered statistically significant. For this reason, the p value for body weight can really only suggest and identify trends in the data that ideally should be confirmed in a larger study. Inasmuch as the tapered dosing of DEX did not attenuate the negative effects of the steroids on bone formation and growth, the cumulative dose of DEX may be the key factor causing the side effects, especially when given in evenly divided doses in the morning and evening.
Urinary NTx has been expressed as a ratio to urinary Cr. Urinary biochemical bone resorption markers adjusted by urinary Cr were either normal (29 -32) or increased (33, 34) . Because urinary Cr excretion is primarily a function of muscle mass, and protein synthesis and lean muscle mass are substantially reduced in subjects taking corticosteroids (35) , it is possible that much of the apparent increase in bone resorption marker reported in previous studies (33, 34 ) is a function of reduced Cr excretion (36) . We used body weight to standardize urinary NTx in the present study. Urinary NTx/weight was lower in all DEX groups compared with respective placebo groups at the end of treatment but did not differ among the three dosing regimens as determined by Z-scores. The lack of effect of dosing regimens on bone resorption may relate to a lesser effect of the corticosteroid on bone resorption than on bone formation (36) . It is believed the inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes are key pathogenetic mechanisms of corticosteroidinduced osteoporosis (37) . In addition, the methods available for evaluating bone resorption have been less reliable than those for bone formation because most of the biochemical markers of bone resorption are measured in urine (16) . A sensitive biochemical marker of bone resorption measured in blood, cross-linked C-telopeptide of Type I collagen (CrossLaps or CTx (38) , was reduced in infant piglets treated with DEX in our previous study (39) .
We conclude that a plasma osteocalcin zenith exists at night in early life. High DEX dose in the morning and low DEX dose in the evening may partially attenuate corticosteroid-induced suppression of bone formation and growth. This physiologic approach to steroid therapy should be studied in VLBW infants to determine whether the desired therapeutic efficacy can be achieved while at the same time minimizing the negative effects on growth and bone turnover.
